Andembry (Garadacimab) for the Treatment of Hereditary Angioedema By: Madaline Spencer| +++++

CLINICAL PERSPECTIVES Andembry (Garadacimab) for the Treatment of Hereditary Angioedema https://checkrare.com/andembry-garadacimab-for-the-treatment-of-hereditary-angioedema/ Timothy Craig, DO, Tenured Professor of Medicine, Pediatrics, and Biomedical Sciences at Penn State University, Principal Investigator of the VANGUARD trial, discusses the recent approval of Andembry (garadacimab) for patients ages 12 years and older with hereditary angioedema (HAE). Recent Clinical Trial Data Testing Inebilizumab to Treat IgG4-Related Diseases https://checkrare.com/recent-clinical-trial-data-testing-inebilizumab-to-treat-igg4-related-diseases/ Matthias Löhr, MD, PhD, Professor of Gastroenterology & Hepatology at Karolinska Institutet, Stockholm, Sweden, discusses recent data from the MITIGATE clinical trial of inebilizumab for the treatment of IgG4-related disease (IgG4-RD). Promising Results for Avapritinib in Observational Trial of Patients With Indolent Systemic Mastocytosis https://checkrare.com/promising-results-for-avapritinib-in-observational-trial-of-patients-with-indolent-systemic-mastocytosis/ Researchers from Berlin, Germany and Beirut, Lebanon have confirmed in a prospective, observational study that patients with uncontrolled symptoms of indolent systemic mastocytosis (ISM) can improve disease control and their quality of life with the use of avapritinib. Avapritinib is a KIT D816V inhibitor that received approval for use in ISM in May 2023. Cutaneous T-Cell Lymphoma: Overview, Management, and Quality-of-Life https://checkrare.com/cutaneous-t-cell-lymphoma-overview-management-and-quality-of-life/ Neha Mehta-Shah, MD, Medical Oncologist at Washington University St. Louis, provides an overview of cutaneous T-cell lymphoma (CTCL), discusses management options, and addresses quality-of-life concerns. Patient Experience With Stevens-Johnson Syndrome https://checkrare.com/patient-experience-with-stevens-johnson-syndrome/ Katie Niemeyer, patient advocate, discusses her experience with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).